Andres Gaviria-Mendoza

2 weeks ago | dialnet.unirioja.es | Manuel Duque |Andres Gaviria-Mendoza |Machado Duque |Machado Alba

Ayuda Buscar en la ayuda Buscar en la ayuda Prevalence of lipid-lowering drug use Autores: Manuel Machado Duque, Andrés Gaviria-Mendoza, Jorge Enrique Machado Alba Localización: Revista Colombiana de Cardiología, ISSN-e 2357-3260, ISSN 0120-5633, Vol. 28, Nº. 1, 2021, págs.

Nov 7, 2024 | mdpi.com | Manuel Enrique Machado-Duque |Andres Gaviria-Mendoza |Luis Fernando Valladales-Restrepo |Álvaro Vallejos-Narváez

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

Jun 5, 2024 | dialnet.unirioja.es | Manuel Duque |Andres Gaviria-Mendoza |Juan Camilo Toro-Jiménez |Santiago Cano-Marín

Effectiveness and safety in the management of chronic inflammatory diseases with etanercept and infliximab biosimilars in Colombian patientsAutores: Manuel Machado Duque, Andrés Gaviria-Mendoza, Juan Camilo Toro-Jiménez, Santiago Cano-Marín, Lorena Osorio-Gutiérrez, Luis Felipe Hernández-Cano, Jorge Enrique Machado AlbaLocalización: Asociación Colombiana de Reumatología, ISSN-e 0121-8123, Vol. 29, Nº. 4, 2022, págs.

Sep 5, 2023 | paperity.org | Manuel Enrique Machado-Duque |Andres Gaviria-Mendoza |Luis Fernando Valladales-Restrepo |Andrés González-Rangel

International Journal of Chronic Obstructive Pulmonary Disease, Jul 2023 A retrospective study on prescription patterns of bronchodilators & other medications used in COPD from a population database with follow-up at 12 & 24 months.

Aug 25, 2023 | mdpi.com | Manuel E Machado-Duque |Maria Fernanda Echeverry-Gutiérrez |Andres Gaviria-Mendoza |Luis F. Valladales-Restrepo

1. IntroductionMigraine is classified as one of the most prevalent chronic disorders in the world. According to the World Health Organization, it affects approximately 15% of the population globally and represents a fifth of neurological consultations [1]. The American Neurological Association makes explicit recommendations, with multiple therapeutic options that are low-cost and adaptable to the individual patient.